🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,263 results for “Cancer” Clear

  1. IRINOTECAN, REGORAFENIB, Stivarga 40 mg film-coated tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  2. ISIS 3521

    IONIS PHARMACEUTICALS INC

    Lung Cancer

    phase 3 mab completed

    1 trial

  3. Identical to the Test product, XGEVA 120 mg solution for injection

    Rein Therapeutics

    Prevention of breast cancer in women with a BRCA1 germline mutation

    phase 3 small molecule active

    1 trial

  4. Imnovid 3 mg hard capsules, Isatuximab, Dexamethason 4 mg JENAPHARM®, JAMP Pomalidomide, JAMP Pomalidomide, Isatuximab, Imnovid 4 mg hard capsules, JAMP Pomalidomide, MONTELUKAST , Pomalidomide Adalvo 4 mg hard capsules, JAMP Pomalidomide, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Imnovid 1 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, DEXAMETHASONE, Imnovid 1 mg hard capsules, Isatuximab, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Dexamethason

    Sanofi Pharma Bristol-Myers Squibb

    Cancer - Plasma cell myeloma recurrent

    phase 3 small molecule active

    1 trial

  5. Intrarosa 6.5 mg pessary

    Istituto Gentili S.r.l.

    Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).

    phase 3 small molecule active

    1 trial

  6. Investigator's choice of Chemotherapy

    Zentalis Pharmaceuticals

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  7. Iodine Contrasts Effectiveness and Safety in Contrast Enhanced Mammography and breast magnetic resonance imaging.

    COLLEGIUM PHARMACEUTICAL, INC

    Breast cancer

    phase 3 other active

    1 trial

  8. Irinotecan Accord, 20 mg/ml, koncentrat do sporządzania roztworu do infuzji, Bendadocel 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cyramza 10 mg/ml concentrate for solution for

    AstraZeneca AB

    Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

    phase 3 small molecule active

    1 trial

  9. Irinotecan HCl-trihydraat Accord 20 mg/ml concentraat voor oplossing voor infusie, Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie, Folinezuur Sandoz 10 mg/ml, oplossing voor injectie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie

    Disc Medicine

    Non-metastatic resectable pancreatic cancer

    phase 3 small molecule active

    1 trial

  10. Irinotecan HCl-trihydraat Fresenius Kabi 20 mg/ml, concentraat voor oplossing voor infusie, Folinezuur Sandoz 10 mg/ml, oplossing voor injectie, Gemcitabine Sandoz 40 mg/ml, concentraat voor oplossing voor infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    non-metastatic (borderline) resectable pancreatic cancer

    phase 3 small molecule active

    1 trial

  11. Ivonescimab 10 mg/kg

    Summit Therapeutics

    Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)

    phase 3 small molecule active

    1 trial

  12. Ivonescimab Injection

    Summit Therapeutics

    Non-Small Cell Lung Cancer

    phase 3 mab active

    2 trials

  13. JEMPERLI 500 mg concentrate for solution for infusion, Docetaxel Hikma 20 mg/1 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 160 mg/8 ml Konzentrat zur Herstellung einer Infusionslösung

    GlaxoSmithKline Biologicals S.A.

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  14. JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Cancer Prevention Pharma (Ireland) Limited

    Patients with localized prostate cancer and high-risk features of relapse.

    phase 3 small molecule active

    1 trial

  15. JNJ-42756493, GEMCITABINE , MITOMYCIN

    Janssen-Cilag International N.V.

    FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  16. JNJ-54767414

    Janssen-Cilag International N.V.

    Precancerous form of blood cancer in the bone marrow

    phase 3 small molecule active

    1 trial

  17. JNJ-56021927

    Cancer Prevention Pharma (Ireland) Limited

    High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy.

    phase 3 small molecule active

    1 trial

  18. JNJ-56021927, Prednison acis 5 mg, Tabletten, ZYTIGA 250 mg tablets, placebo to match JNJ-56021927/Apalutamide, -

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  19. JNJ-61186372, Carboplatin 10 mg/ml Intravenous Infusion, CARBOPLATIN , Pemetrexed Seacross 500 mg powder for concentrate for solution for infusion, PEMETREXED

    Janssen-Cilag International N.V.

    EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  20. JNJ-61186372, Erbitux 5 mg/mL solution for infusion, Erbitux 5 mg/mL solution for infusion

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    phase 3 small molecule active

    1 trial

  21. JNJ-61186372, JNJ-73841937, JNJ-61186372

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  22. JNJ-73841937, Pemetrexed Seacross 500 mg powder for concentrate for solution for infusion, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung Carboplatin, JNJ-61186372, CARBOPLATIN , Carboplatin 10 mg/ml Intravenous Infusion, PEMETREXED

    Janssen-Cilag International N.V.

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  23. JNJ-78278343, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, JNJ-78278343, Prednison acis 5 mg, Tabletten, DOCETAXEL , PREDNISONE

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  24. JZP598, GEMCITABINE , TRASTUZUMAB , CAPECITABINE , VINORELBINE , ERIBULIN

    Jazz Pharmaceuticals Ireland Limited

    Metastatic HER2-positive breast cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources